Cargando…
Promising FDA-approved drugs with efflux pump inhibitory activities against clinical isolates of Staphylococcus aureus
BACKGROUND AND OBJECTIVES: Staphylococcus aureus is an opportunistic pathogen that causes wide range of nosocomial and community-acquired infections which have spread worldwide leading to an urgent need for developing effective anti-staphylococcal agents. Efflux is an important resistance mechanism...
Autores principales: | Abdel-Karim, Safaa Abdel-Aal Mohamed, El-Ganiny, Amira Mohamed Ali, El-Sayed, Mona Abdelmonem, Abbas, Hisham Abdelmonem Abdelhamid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337675/ https://www.ncbi.nlm.nih.gov/pubmed/35905077 http://dx.doi.org/10.1371/journal.pone.0272417 |
Ejemplares similares
-
Repurposing pantoprazole and haloperidol as efflux pump inhibitors in azole resistant clinical Candida albicans and non-albicans isolates
por: El-Ganiny, Amira M., et al.
Publicado: (2022) -
In silico screening of potent inhibitors against COVID-19 key targets from a library of FDA-approved drugs
por: Elmorsy, Mohammad A., et al.
Publicado: (2021) -
Formulation and characterization of chlorhexidine HCl nanoemulsion as a promising antibacterial root canal irrigant: in-vitro and ex-vivo studies
por: Abdelmonem, Rehab, et al.
Publicado: (2019) -
Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
por: Roberts, Robert
Publicado: (2018) -
Function and Inhibitory Mechanisms of Multidrug Efflux Pumps
por: Nishino, Kunihiko, et al.
Publicado: (2021)